Cytosorbents Corporation (CTSO)
1.03
0.01 (0.98%)
At close: Apr 17, 2025, 3:59 PM
1.03
-0.07%
After-hours: Apr 17, 2025, 05:53 PM EDT
0.98% (1D)
| Bid | 0.99 |
| Market Cap | 64.38M |
| Revenue (ttm) | 37.44M |
| Net Income (ttm) | -20.72M |
| EPS (ttm) | -0.38 |
| PE Ratio (ttm) | -2.71 |
| Forward PE | -7.36 |
| Analyst | Buy |
| Ask | 1.06 |
| Volume | 48,628 |
| Avg. Volume (20D) | 103,712 |
| Open | 1.02 |
| Previous Close | 1.02 |
| Day's Range | 0.97 - 1.04 |
| 52-Week Range | 0.70 - 1.61 |
| Beta | 1.17 |
About CTSO
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complication...
Industry Medical - Devices
Sector Healthcare
IPO Date Aug 8, 2006
Employees 149
Stock Exchange NASDAQ
Ticker Symbol CTSO
Website https://www.cytosorbents.com
Analyst Forecast
According to 4 analyst ratings, the average rating for CTSO stock is "Buy." The 12-month stock price forecast is $6.5, which is an increase of 531.07% from the latest price.
Stock ForecastsNext Earnings Release
Cytosorbents Corporation is scheduled to release its earnings on May 8, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
6 months ago
-10%
CytoSorbents shares are trading lower. The company...
Unlock content with
Pro Subscription
8 months ago
+17.48%
Cytosorbents shares are trading higher after EF Hutton initiated coverage on the stock with a Buy rating and announced a price target of $10.
